{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:28:22Z","timestamp":1793665702315,"version":"4.5.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Hormone receptor\u2013positive (HR\n                      <jats:sup>+<\/jats:sup>\n                      )\/HER2\n                      <jats:sup>\u2212<\/jats:sup>\n                      breast cancer (BC) exhibits limited sensitivity to neoadjuvant chemotherapy, with low pathologic complete response (pCR) rates. While CDK4\/6 inhibitors (CDK 4\/6i) combined with endocrine therapy have demonstrated efficacy, the immunogenicity of HR\n                      <jats:sup>+<\/jats:sup>\n                      \/HER2\n                      <jats:sup>\u2212<\/jats:sup>\n                      tumors remains low, limiting the benefit of immunotherapy. Emerging evidence suggests potential synergy between CDK4\/6 inhibition and immune checkpoint blockade. This study explores the neoadjuvant combination of adebrelimab, dalpiciclib, and endocrine therapy in patients with stage II\u2013III HR\n                      <jats:sup>+<\/jats:sup>\n                      \/HER2\n                      <jats:sup>\u2212<\/jats:sup>\n                      BC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This single-arm, exploratory study enrolled postmenopausal women with histologically confirmed stage II\u2013III HR\n                      <jats:sup>+<\/jats:sup>\n                      \/HER2\n                      <jats:sup>\u2212<\/jats:sup>\n                      BC. Eligible patients received neoadjuvant therapy comprising adebrelimab (1200 mg intravenously, day 1), dalpiciclib (125 mg orally, once daily on days 1\u201321), and letrozole. Treatment was administered over five 28-day cycles prior to surgery. The primary endpoint was total pCR (tpCR; defined as ypT0-is\/ypN0).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Between October 2024 and March 2025 patients (median age 61.5\u00a0years) with stage II\u2013III HR\n                      <jats:sup>+<\/jats:sup>\n                      \/HER2\n                      <jats:sup>\u2212<\/jats:sup>\n                      BC were enrolled. Most patients had T2 tumors (85%) and N1 disease (55%). All patients received \u22651 treatment cycle; 17 completed surgery. Radiological partial response was observed in 13 patients (65%), with an overall objective response rate (ORR) of 65%. One patient (5%) achieved tpCR. Three patients discontinued due to adverse events (AE; one death, one hepatitis, and one pneumonia). Common grade \u2265 3 AEs included neutropenia (50%), leukopenia (25%), and elevated liver enzymes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      This triplet regimen demonstrated modest clinical activity in HR\n                      <jats:sup>+<\/jats:sup>\n                      \/HER2\n                      <jats:sup>\u2212<\/jats:sup>\n                      early BC, with the safety profile of this regimen remains a concern and warrants particular attention in clinical practice.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000004982","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:01:51Z","timestamp":1771869711000},"page":"11737-11743","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Adebrelimab in combination with dalpiciclib and endocrine therapy as neoadjuvant treatment for HR+\/HER2\u2212 early breast cancer: an exploratory study"],"prefix":"10.1097","volume":"112","author":[{"given":"Min","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhao","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanxuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal Song","family":"Zhang","sequence":"additional","affiliation":[{"name":"Emory College of Arts and Sciences, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"},{"name":"NHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, Heilongjiang, China"},{"name":"State Key Laboratory of Frigid Zone Cardiovascular Disease, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"R1-20261102","first-page":"477\u201395","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"Ca A Cancer J Clinicians"},{"key":"R2-20261102","doi-asserted-by":"crossref","first-page":"1485\u2013505","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"R3-20261102","doi-asserted-by":"crossref","first-page":"102669","DOI":"10.1016\/j.ctrv.2023.102669","article-title":"Neoadjuvant therapy in hormone receptor-positive\/HER2-negative breast cancer","volume":"123","author":"Cantini","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"R4-20261102","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.3390\/ijms21103528","article-title":"Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives","volume":"21","author":"Barchiesi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R5-20261102","doi-asserted-by":"crossref","first-page":"249\u201356","DOI":"10.1016\/S1470-2045(18)30001-9","article-title":"Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study","volume":"19","author":"Gianni","year":"2018","journal-title":"Lancet Oncol"},{"key":"R6-20261102","doi-asserted-by":"crossref","first-page":"566\u201380","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR(+)\/HER2(-) breast cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R7-20261102","doi-asserted-by":"crossref","first-page":"33\u201343","DOI":"10.1016\/S1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"key":"R8-20261102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13058-025-01976-0","article-title":"Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+\/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study","volume":"27","author":"Zhang","year":"2025","journal-title":"Breast Cancer Res"},{"key":"R9-20261102","doi-asserted-by":"crossref","first-page":"2978\u201394","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The CDK4\/6 Inhibitor Abemaciclib Induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep"},{"key":"R10-20261102","doi-asserted-by":"crossref","first-page":"2564\u201381","DOI":"10.1158\/2159-8290.CD-20-1540","article-title":"Inhibition of CDK4\/6 promotes CD8 T-cell memory formation","volume":"11","author":"Heckler","year":"2021","journal-title":"Cancer Discovery"},{"key":"R11-20261102","doi-asserted-by":"crossref","first-page":"103580","DOI":"10.1016\/j.breast.2023.103580","article-title":"Neoadjuvant Nivolumab + Palbociclib + Anastrozole for Oestrogen Receptor-positive\/human Epidermal Growth Factor Receptor 2-negative Primary Breast Cancer: Results from CheckMate 7A8","volume":"72","author":"Jerusalem","year":"2023","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"R12-20261102","doi-asserted-by":"crossref","first-page":"e007126","DOI":"10.1136\/jitc-2023-007126","article-title":"Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)","volume":"11","author":"Masuda","year":"2023","journal-title":"J ImmunoTherapy of Cancer"},{"key":"R13-20261102","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41523-022-00482-2","article-title":"Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: phase 1b study","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"R14-20261102","doi-asserted-by":"crossref","first-page":"739\u201347","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"R15-20261102","first-page":"411\u201321","article-title":"A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+\/HER2- breast cancer-FINEST study","volume":"45","author":"Chen","year":"2025","journal-title":"Cancer Comms (London, England)"},{"key":"R16-20261102","first-page":"10:100081","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of Artificial Intelligence","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R17-20261102","doi-asserted-by":"crossref","first-page":"1904\u201309","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nature Med"},{"key":"R18-20261102","doi-asserted-by":"crossref","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"R19-20261102","doi-asserted-by":"crossref","first-page":":e170503","DOI":"10.1172\/JCI170503","article-title":"Pulmonary toxicity of immune checkpoint immunotherapy","volume":"134","author":"Ghanbar","year":"2024","journal-title":"J Clin Invest"},{"key":"R20-20261102","doi-asserted-by":"crossref","first-page":"1266850","DOI":"10.3389\/fimmu.2024.1266850","article-title":"Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management","volume":"15","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"R21-20261102","doi-asserted-by":"crossref","first-page":"3727\u201339","DOI":"10.1016\/j.apsb.2021.10.003","article-title":"Mechanisms of immune checkpoint inhibitor-mediated liver injury","volume":"11","author":"Shojaie","year":"2021","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"R22-20261102","doi-asserted-by":"crossref","first-page":":e2022072908182023c","DOI":"10.1084\/jem.2022072908182023c","article-title":"PD-1 blockade and CDK4\/6 inhibition augment nonoverlapping features of T cell activation in cancer","volume":"220","author":"Ali","year":"2023","journal-title":"J Exp Med"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000004982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:02:24Z","timestamp":1793664144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000004982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000004982","relation":{},"ISSN":["1743-9159","1743-9191"],"issn-type":[{"value":"1743-9159","type":"electronic"},{"value":"1743-9191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"2025-10-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}